Morgan Stanley lowered the firm’s price target on Rocket Companies (RKT) to $13 from $16 and keeps an Equal Weight rating on the shares. The ...
Rocket Lab is poised for long-term growth in the booming space industry, with significant revenue and technological ...
Jefferies initiated a "buy" rating on Rocket Pharmaceuticals, based on the biotech firm's experimental gene therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback